Identity

Alias
Central neurofibromatosis
Bilateral acoustic neurofibromatosis Bilateral acoustic neurinoma Bilateral acoustic schwannomas Inheritance Autosomal dominant with almost complete penetrance; frequency is 3/10 5 newborns; neomutation represent 50% of cases; variable expressivity from mild disease through life (Gardner type) to severe condition at young age (Wishart type: with more than 3 tumours).
Clinics
Note NF2 is an hamartoneoplastic syndrome; hamartomas are localized tissue proliferations with faulty differenciation and mixture of component tissues; they are heritable malformations that have a potential towards neoplasia.
Phenotype and clinics
Bilateral vestibular (8th cranial pair) schwannomas; other central or peripheral nerve schwannomas; meningiomas; ependymomas. Hearing loss (average age 20 yrs), tinnitus, imbalance, headache, cataract in 50%, facial paralysis. Café-au-lait spots and cutaneous and peripheral neurofibromas may be present, but far less extensively than in neurofibromatosis type 1.
Neoplastic risk
NF2 cases represent about 5 % of schwannomas and meningiomas (i.e. risk increased by 2000), appearing at the age of 20, while they are found in the general population at the age of 50 and over.
Prognosis
These tumours are usually benign, but their location within the central nervous system gives them a grave prognosis; patients with the Wishart severe form usually do not survive past 50 yrs.
Cytogenetics
Inborn conditions
Normal.
Cytogenetics of cancer
Chromosome 22 loss is very frequent both in sporadic and in NF2 schwannomas and meningiomas.
Genes involved and proteins
NF2 (neurofibromatosis 2)
Location: 22q12 DNA/RNA Description: 17 exons (1-15, 17 constitutive, 16 alternatively spliced). Protein Description: Isoform 1 595 amino acids, isoform 2 590 amino acids (due to inclusion of exon 16 in transcript); contains a FERM domain and a large a helix domain. Expression: Wide. Function: Membrane-cytoskeleton anchor; tumour suppressor. Homology: Band 4.1 family , ezrin, radixin, moesin. Mutations Germinal: Germ-line mutations in NF2 patients lead to protein truncation; splice-site or missense mutations are also found; phenotype-genotype correlations are observed (i.e. that severe phenotype are found in cases with protein truncations rather than those with amino acid substitution). Somatic: Mutation and allele loss events in tumours in neurofibromatosis type 2 and in sporadic schwannomas and meningiomas are in accordance with the two-hit model for neoplasia.
